Receps Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN U24239TG2022PLC162610 Incorporated 12 May 2022 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Public Limited Company pharma MSME · Micro
Revenue · FY 2025
₹9.2 Cr
▲ 65% YoY
Net loss · FY 2025
₹70,000
Net margin -0.1%
EBITDA · FY 2025
₹3.14 Cr
EBITDA margin 34.1%
Authorised capital
₹15 Lakh
Registered with MCA
Paid-up capital
₹10 Lakh
Issued & subscribed
Company age
4 yrs
Est. 2022
Employees · EPFO
89
Provident fund records
Directors on board
3
As per MCA filings

About Receps Limited

Data last updated:

Receps Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Visakha Pharmacity Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 12 May 2022.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24239TG2022PLC162610. Its GSTIN is 37AALCR8634D1Z3 (Andhra Pradesh).

The company has an authorised share capital of ₹15 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors including Eshwar Reddy Purmandla and Popuri Pandari Lal Krishna.

Its last annual general meeting (AGM) was held on 11 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 136/2 And 4 7th Floor Ramky Grandiose Gachibowli, Hyderabad, Telangana, India – 500032.

As per the financials filed for FY 2025, the company reported a revenue of ₹9.2 Cr, a growth of 65% compared to the previous year. For the same year it recorded a net loss of ₹70,000 (net margin -0.1%) and EBITDA of ₹3.14 Cr (EBITDA margin 34.1%).

The company has about 89 employees on its provident fund (EPFO) records.

Receps Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-09-0056575). The current compliance status is marked as compliant by the Registrar of Companies.

Company details

CIN U24239TG2022PLC162610
Registration Number 162610
Incorporation Date 12 May 2022
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Parent Company Visakha Pharmacity Limited
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-TS-09-0056575

Recognitions & Rankings of Receps

MSME (Udyam registered) Ministry of MSME
Category
Micro (2023-24)
Udyam number
UDYAM-TS-09-0056575

Contact details

Receps Limited's registered office is in Hyderabad, Telangana. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    136/2 And 4 7th Floor Ramky Grandiose Gachibowli, Hyderabad, Telangana, India – 500032
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Receps Limited, buy the company report.

Comprehensive company report
Receps Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Business activity

The main business activity of Receps is professional, scientific and technical. In detail, this covers scientific research and development.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
MProfessional, Scientific and TechnicalM5Scientific research and development

To see the full business activity and turnover split of Receps Limited, buy the company report.

Financials of Receps Limited

FY 2025 filings available

Receps Limited reported revenue of ₹9.2 Cr (up 65% YoY) for FY 2025.

Revenue · FY 2025
₹9.2 Cr ▲ 65%
Net loss · FY 2025
₹70,000 margin -0.1%
EBITDA · FY 2025
₹3.14 Cr margin 34.1%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 65%
EBITDA CAGR growth
1 year
▲ 91%

Revenue rose 65% in the latest year. EBITDA rose 91% in the latest year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹3.14 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)-₹70,000
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23
Profitability
EBITDA Margin34.1%
Net Profit Margin-0.1%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Receps Limited, buy the company report.

Board of directors of Receps Limited

Receps has 3 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors

Peer comparison

Receps Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Novumgen Private Limited₹9.49 Cr (FY 2024)77.0%Vadodara, Gujarat, India
Receps Limitedthis company₹9.2 Cr (FY 2025)-₹70,000-0.1%65.0%89Hyderabad, Telangana, India
Taraasian Drugs Private Limited₹9.17 Cr (FY 2025)21.0%Aurangabad, Maharashtra, India
Airis Pharma Private Limited₹9.06 Cr (FY 2024)29.0%Telangana, India

To see the full peer comparison of Receps Limited, buy the company report.

Auditor

Receps Limited is audited by A B V & Associates for the financial year 2023.

Auditor firmFinancial yearFirm registration number
A B V & AssociatesFY 2023004937S

Shareholding

The shareholding of Receps Limited is on record for FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2023
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Receps Limited, buy the company report.

MSME payment delays

Receps Limited has 2 MSME Form 1 returns on record for the period ending Mar 2023, listing 38 overdue payments to 4 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (4 of 4)

SupplierAmount dueDue sinceReported on
Sri Sai Durga Scientifics
an individual supplier
Chromatography World
Production Needs Gases Private Limited

To see the full MSME payment records of Receps Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Receps Limited has a workforce of 89 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
89
Active EPFO establishments
1
Employee growth
-4.3%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-2789
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23

To see the full employee and EPFO history of Receps Limited, buy the company report.

GST

Receps has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
37AALCR8634D1Z3Andhra PradeshActive01 Jul 2022

To see the full GST registrations and return filing status of Receps Limited, buy the company report.

Recent activity

Receps Limited has 9 board changes on record since 2022: 3 appointments and 6 cessations. The latest: Siva Satyanarayana Reddy Manda was appointed as Nominee Director on 18 Mar 2024.

AGM
Receps Limited last Annual general meeting of members was held on 11 Sep 2025 as per latest MCA records.
Filing
Receps Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Appointed
Siva Satyanarayana Reddy Manda was appointed as Nominee Director.
Ceased
Eshwar Reddy Purmandla ceased to be Additional Director.
Ceased
Popuri Pandari Lal Krishna ceased to be Additional Director.
Ceased
Deleep Cherukuri ceased to be Director.
Appointed
Eshwar Reddy Purmandla was appointed as Director.
Appointed
Popuri Pandari Lal Krishna was appointed as Director.
Ceased
Ramakrishna Reddy Munnamgi ceased to be Director.
Ceased
Udayampalayam Palanisamy Senthilkumar ceased to be Additional Director.
Ceased
Vullangula Siva Prasad ceased to be Director.
Incorporation
12 May 2022
Receps Limited was registered on 12 May 2022 with Roc Hyderabad & aged 4 years 6 months as per MCA records.

Frequently asked questions

Receps is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 12 May 2022 (4+ years old) and is registered under CIN U24239TG2022PLC162610.

Receps has 3 current directors:

The latest financial statements of Receps on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 11 September 2025. Year-wise statements from FY 2023 are in the company report.

The GSTIN of Receps is 37AALCR8634D1Z3, registered in Andhra Pradesh.

The CIN (Corporate Identification Number) of Receps is U24239TG2022PLC162610. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Receps was incorporated on 12 May 2022, making it 4+ years old. It is registered with the Registrar of Companies, Hyderabad.

The peers of Receps by revenue are Novumgen Private Limited, Taraasian Drugs Private Limited, Airis Pharma Private Limited, all in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development).

Siva Satyanarayana Reddy Manda was appointed as Nominee Director on 18 Mar 2024. Eshwar Reddy Purmandla ceased to be Additional Director on 29 Sep 2023. Popuri Pandari Lal Krishna ceased to be Additional Director on 29 Sep 2023. Receps has 9 board changes on record in total.

Yes, Receps is registered as a micro enterprise under Udyam registration (number: UDYAM-TS-09-0056575).

Receps has 2 MSME Form 1 returns on record for the period ending Mar 2023, listing 38 overdue payments to 4 micro and small suppliers. The latest return was filed on 27 Aug 2023.

The registered office of Receps is at 1362 And 4 7th Floor Ramky Grandiose Gachibowli, Hyderabad, Telangana, India – 500032.

Receps operates in the pharma industry, in the drug formulation and development segment.